Algernon Pharmaceuticals Inc (AGNPF)

[tcm55]

Some interesting of Bth/NASH/Agn chart (?) analysis with emotional accents.

A cooperative relationship with BLO to use Bth's medical Breathalyzer (Yost) FAIMS research made sense to me after the '18/'19 Pot runups. An easier target than THC9 and it woulda/coulda/shoulda have been relevant as the COVID pandemic started
But
It's 2022 now.
But.
We all wish for successful repurposing Drug strategies with IBD/IPF/CKD as the company had to change directions. IMO..

COVID came as Agn prioritized IPF/CC and we all wished for Ifenprodil to quickly move through Clinical Trials in South Korea and internationally.
Delay issues finally led to the 'expected' Dec 2020 interim review (fiasco) trying 'to keep Agn's COVID efforts relevant" as the first wave waned and vaccines became available.
Ifenprodil did not prove effective enough for COVID type illnesses specifically and costs/medical needs made a Phase 3 CT not a viable direction.
Some of the positive data from that CT relates to IPF/CC uses of Ifenprodil. We will see.

Back to 2022.
Sharp eyes caught that Ifenprodil enhanced cancer tumor treatment successes at a statistically significant level. Agn is active in pursuit of this now licensed IP ect.

Sharp leadership caught that there was successful research of micro dosing DMT for Stroke. That IP was licensed before others could grab it.

Congratulations to the Algernonn team. IMO. ..

No buts. Buy-Hold-Sell...GLTA...

.